GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Panacea Biotec PANACEABIO.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

360.65

+4.84%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2025

Revenue

₹5.59bn

FY2016FY2025

Net income

−₹83.7m

FY2016FY2025

Free cash flow

−₹776.7m

FY2016FY2025

Shareholders' equity

₹8.35bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₹5.59bn₹5.59bn₹4.60bn₹6.61bn₹6.25bn₹5.44bn₹4.57bn₹5.96bn₹5.58bn₹6.53bn
Operating income−₹209.3m−₹136.5m−₹57.5m₹16.22bn₹354.5m−₹272.6m₹1.66bn₹400.2m₹198.7m₹1.00bn
Net income−₹83.7m−₹11.7m−₹332.4m₹10.78bn−₹1.48bn−₹1.94bn₹377.3m−₹739.8m−₹544.8m−₹182.9m
Diluted earnings per share-1.37-0.19-5.39175.84-24.11-31.726.16-12.07-8.90-2.99

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₹12.90bn₹12.41bn₹12.71bn₹17.59bn₹11.78bn₹13.90bn₹13.76bn₹16.08bn₹18.00bn₹18.03bn
Cash and short-term investments₹1.46bn₹1.51bn₹2.07bn₹5.49bn₹1.49bn₹960.2m₹234.8m₹252.5m₹143.8m₹159.1m
Total liabilities₹4.55bn₹3.99bn₹4.28bn₹8.82bn₹14.06bn₹11.92bn₹10.25bn₹12.99bn₹14.44bn₹13.99bn
Debt₹222.1m₹209.9m₹201.6m₹341.0m₹8.20bn₹6.17bn₹1.16bn₹7.36bn₹9.05bn₹9.75bn
Shareholders' equity₹8.35bn₹8.42bn₹8.44bn₹8.77bn−₹2.29bn₹1.99bn₹3.50bn₹3.09bn₹3.56bn₹4.04bn
Shares outstanding61m61m62m61m61m61m61m61m61m61m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₹273.7m₹34.7m−₹4.22bn−₹1.08bn₹1.07bn−₹302.3m₹1.05bn₹1.18bn₹1.31bn₹906.9m
Capital spending−₹503.1m−₹828.8m−₹409.5m−₹125.1m−₹217.6m−₹69.1m−₹47.8m−₹152.2m−₹238.9m−₹113.2m
Free cash flow−₹776.7m−₹794.1m−₹4.63bn−₹1.21bn₹848.9m−₹371.4m₹997.4m₹1.03bn₹1.07bn₹793.7m

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Revenue₹1.65bn₹1.41bn₹1.67bn₹1.33bn₹1.63bn₹1.47bn₹1.16bn₹1.36bn
Operating income₹60.6m−₹234.3m₹17.5m−₹75.9m₹17.5m₹10.9m−₹227.2m−₹148.5m
Net income₹39.8m−₹139.2m₹40.5m−₹18.9m₹45.2m₹48.0m−₹158.0m−₹16.6m
Diluted earnings per share0.65-2.270.66-0.310.740.79-2.59-0.27
Cash from operations—−₹7.0m—−₹369.0m—₹96.0m—₹150.0m
Capital spending—−₹253.0m—−₹344.0m—−₹158.0m—−₹264.0m
Free cash flow—−₹260.0m—−₹713.0m—−₹62.0m—−₹114.0m
Total assets—₹12.54bn—₹12.90bn—₹12.43bn—₹12.41bn
Cash and short-term investments—₹1.28bn—₹1.79bn—₹2.02bn—₹1.85bn
Debt—₹229.0m—₹222.1m—₹215.7m—₹209.9m
Shareholders' equity—₹8.26bn—₹8.35bn—₹8.33bn—₹8.42bn

Financial ratios

Data as of 27 Sept 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-5.9%-0.7%0.9%3.8%247.3%5.3%—
Net margin-0.8%-1.5%-0.2%-7.3%163.6%-23.9%—
Return on equity-0.6%-1.0%-0.1%-3.9%123.0%64.6%—
Return on assets-0.4%-0.6%-0.1%-2.6%61.3%-12.5%—
Free cash flow yield3.1%1.0%3.4%-16.6%-4.2%5.6%—
Revenue growth14.4%1.3%20.8%-30.7%6.7%15.0%—
Earnings growth-35.8%613.6%-96.5%-103.1%-830.1%-24.0%—
Current ratio1.47x1.49x1.57x1.71x1.28x1.14x—
Debt to equity0.03x0.03x-0.07x0.02x0.04x-3.58x—
Equity ratio66.1%64.7%67.9%66.4%49.8%-19.4%—
Interest coverage-6.23x-1.05x1.41x3.89x9.01x0.18x—
R&D as a share of sales—7.7%6.7%7.2%1.6%6.3%2.0%
Buybacks as a share of market value0.0%-0.3%0.9%-0.5%-0.0%-0.1%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-5.4%0.5%-2.0%
Operating income—-5.1%—
Net income—-46.7%-22.5%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-3.1%70.6%46.6%30.5%
Net margin-0.9%46.2%20.3%7.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-278.0-2170.6-31.10.8-8.3-7.519.5-12.2-25.0-36.2
Price to sales4.24.52.21.32.02.71.61.52.41.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 19 Sept 2011.

FY2012FY2011FY2009FY2008FY2007FY2006FY2005FY2004
Paid in the year0.750.251.001.001.001.501.001.00
  • 10-for-1 split · 3 Feb 2003

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.